On the other hand, mutations in RB1 (p=0.29, Figure 2D) and BRAF (p=0.17, Figure 2E), which were enriched in the LCNEC group, showed trends of increased survival. The gene discussed is BRAF; the disease is large cell neuroendocrine carcinoma.